Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Decision Curves and Relative Utility Curves.

Baker SG.

Med Decis Making. 2019 May 20:272989X19850762. doi: 10.1177/0272989X19850762. [Epub ahead of print] No abstract available.

PMID:
31104590
2.

Deriving Real-World Insights From Real-World Data.

Baker SG.

Ann Intern Med. 2019 May 7;170(9):664-665. doi: 10.7326/L19-0084. No abstract available.

PMID:
31060070
3.

Correction to "Latent class instrumental variables: A clinical and biostatistical perspective".

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2019 Feb 28;38(5):901. doi: 10.1002/sim.8035. Epub 2018 Oct 30. No abstract available.

PMID:
30761594
4.

Cancer Screening Markers: A Simple Strategy to Substantially Reduce the Sample Size for Validation.

Baker SG.

Med Decis Making. 2019 Feb;39(2):130-136. doi: 10.1177/0272989X18819792. Epub 2019 Jan 18.

PMID:
30658540
5.

Early Development of Value of Information Methods.

Baker SG.

Med Decis Making. 2018 Nov;38(8):903. doi: 10.1177/0272989X18809372. No abstract available.

PMID:
30403581
6.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Baker SG.

Ann Intern Med. 2018 Apr 17;168(8):606-607. doi: 10.7326/L17-0736. No abstract available.

PMID:
29677260
7.

Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.

Baker SG.

Stat Med. 2018 Apr 15;37(8):1406. doi: 10.1002/sim.7603. Epub 2018 Jan 22. No abstract available.

PMID:
29529710
8.

Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop.

Young MR, Wagner PD, Ghosh S, Rinaudo JA, Baker SG, Zaret KS, Goggins M, Srivastava S.

Pancreas. 2018 Feb;47(2):135-141. doi: 10.1097/MPA.0000000000000973.

9.
10.

The summary test tradeoff: a new measure of the value of an additional risk prediction marker.

Baker SG.

Stat Med. 2017 Dec 10;36(28):4491-4494. doi: 10.1002/sim.7132. No abstract available.

11.

Editorial: Challenges in Quantifying Overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx064. No abstract available.

12.

Simple Decision-Analytic Functions of the AUC for Ruling Out a Risk Prediction Model and an Added Predictor.

Baker SG.

Med Decis Making. 2018 Feb;38(2):225-234. doi: 10.1177/0272989X17732994. Epub 2017 Oct 12.

13.

Validity of Surrogate End Points for Prostate Cancer.

Baker SG.

JAMA Oncol. 2018 Jan 1;4(1):129-130. doi: 10.1001/jamaoncol.2017.0334. No abstract available.

PMID:
28859193
14.

Instrumental variable meta-analysis Comment on: Adjustment for compliance behavior in trials of epidural analgesia in labor using instrumental variable meta-analysis.

Baker SG, Lindeman KS.

J Clin Epidemiol. 2017 Nov;91:146-147. doi: 10.1016/j.jclinepi.2017.07.013. Epub 2017 Aug 9. No abstract available.

PMID:
28802676
15.

Evaluating Markers for Guiding Treatment.

Baker SG, Bonetti M.

J Natl Cancer Inst. 2016 May 18;108(9). pii: djw101. doi: 10.1093/jnci/djw101. Print 2016 Sep.

16.

The latent class twin method.

Baker SG.

Biometrics. 2016 Sep;72(3):827-34. doi: 10.1111/biom.12460. Epub 2016 Jan 11.

17.

RE: Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection.

Baker SG.

J Natl Cancer Inst. 2015 Sep;107(9). doi: 10.1093/jnci/djv215. No abstract available.

18.

Latent class instrumental variables: a clinical and biostatistical perspective.

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2016 Jan 15;35(1):147-60. doi: 10.1002/sim.6612. Epub 2015 Aug 4. Erratum in: Stat Med. 2019 Feb 28;38(5):901.

19.

Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.

Baker SG, Kramer BS.

J Clin Oncol. 2015 Aug 10;33(23):2578-80. doi: 10.1200/JCO.2014.58.0092. Epub 2015 Jun 29. No abstract available.

Supplemental Content

Loading ...
Support Center